FLT3 and acute myeloid leukemia: Setanaxib, an inhibitor with anti-NOX1 and NOX4 functions, has anti-proliferative effects on both FLT3-ITD-positive and negative AML cells, and has strong synergistic effects with cytotoxic drugs anthracyclines such as daunorubicin.